Managing Premenstrual Symptoms – Treatment

(Published June 2008) More than 80 different therapies have been suggested for the treatment of PMS/PMDD, resulting in much conflicting information and many unwarranted claims of effectiveness. No single intervention is effective for all women, …

(Published June 2008)

More than 80 different therapies have been suggested for the treatment of PMS/PMDD, resulting in much conflicting information and many unwarranted claims of effectiveness. No single intervention is effective for all women, and there is a substantial placebo response with many therapies.1 It may take time and several attempts to determine the safest and most effective treatment for an individual patient.

Treatment of PMS/PMDD is best approached in a stepwise fashion, beginning with lifestyle modifications and progressing to nutritional supplementation, nonpharmacologic therapy, and nonprescription and prescription medications. Conservative treatment has proved beneficial in many women and should be considered first-line therapy in women with mild symptoms and adjunctive therapy in all others.

Table 2 shows a hierarchical approach to the treatment of PMS/PMDD that matches the aggressiveness of the approach to the severity of symptoms. Selection of therapy can also be matched to the nature of the symptoms. For instance, women with a PMS diagnosis presenting with bloating and breast tenderness as her key symptoms (Level 2) may be prescribed spironolactone, if there are no contraindications, to minimize this specific symptom.


Table 2. Hierarchical Approach to the Treatment of PMS and PMDD2
Move to the next level if the chosen approach is ineffective for two to four cycles.Level 1. PMS, mild to moderate:

  • Lifestyle: Aerobic exercise, nutritional changes (reduction of caffeine, salt, alcohol; increase in complex carbohydrates)
  • Nonprescription drugs:
    • Calcium, 1,000 g or magnesium 400 g, once daily
    • Chaste tree extract (Vitex agnus-castus) 30-40 mg daily
  • Relaxation therapy
  • Cognitive behavioral therapy

Level 2. PMS with physical problems predominating:

  • Spironolactone, 25 mg daily, for breast tenderness and bloating
  • OCs (regular or long cycle) or MPA for breast and abdominal pain
  • NSAIDs during the luteal phase

Level 3. PMS or PMDD with mood symptoms predominating:

  • SSRIs* on symptom days only
  • Continuous SSRIs*
  • Buspirone during the luteal phase

Level 4. PMDD not responsive to therapy for Levels 1–3:

  • Continuous high-dose progestin (e.g., oral MPA, 20–30 mg daily; DMPA, 150 mg every 3 months; Yaz®)
  • GnRH (usual dose) with add-back estrogen/progestin if continued beyond 6 months
* If initial SSRI is ineffective or not tolerated, try at least two additional types of SSRIs (including venlafaxine) before abandoning this type of agent.

GnRH = gonadotropin-releasing hormone; MPA = medroxyprogesterone acetate; DMPA = depo-medroxyprogesterone acetate; NSAID = nonsteroidal anti-inflammatory drug; OC = oral contraceptive; PMS = premenstrual syndrome; PMDD = premenstrual dysphoric disorder; SSRI = selective serotonin reuptake inhibitor.


Treatment must be individualized and often requires a combination of approaches. Long-term treatment of PMS/PMDD is typically required, as evidence indicates that symptoms return when treatment is discontinued.3

Lifestyle Changes

Treatment of mild premenstrual disorders begins with 2–3 months of lifestyle changes during the same time the woman is charting her symptoms. Based on medical history, the modifications listed in Table 3 can be suggested.


Table 3. Lifestyle Modifications for Mild PMS4 – 21

  • Eat frequent and smaller portions of foods high in complex carbohydrates
  • Reduce:
    • Salt
    • Sugar
    • Caffeine
    • Dairy products (or take lactase enzymes)
    • Alcohol

Nutritional Supplementation

  • Vitamin B6, up to 100 mg per day (limited benefit)
  • Vitamin E, up to 600 IU per day (limited benefit)
  • Calcium carbonate, 1,200 mg per day, with vitamin D, 400 IU per day for absorption, in divided doses*
  • Magnesium, up to 500 mg per day


  • Patient education/counseling about PMS/PMDD (See Appendix A for patient resources.)
  • Regular aerobic exercise (20–30 minutes, 3 times per week)
  • Yoga
  • Relaxation and stress management
  • Anger management
  • Self-help support groups
  • Individual and couples therapy
  • Cognitive-behavioral therapy*
  • Smoking cessation
  • Regular sleep
  • Light therapy

Nonprescription Medications

  • NSAIDs (naproxen, mefenamic acid, ibuprofen, etc.) in doses commonly used in the treatment of menstrual cramps
*Evidence based


Pharmacologic Treatment

Selective Serotonin Reuptake Inhibitors

Selective serotonin reuptake inhibitors (SSRIs) should be considered first-line therapy for the pharmacologic treatment of severe premenstrual symptoms.22 An estimated 60% of women respond to this class of drugs.15 SSRIs have been shown to be effective for both PMS and PMDD9 and to be equally efficacious for the treatment of physical, behavioral, and psychological symptoms.23

Safety and Side Effects

The long-term safety of SSRIs has been demonstrated based on their widespread use in treating depression.1 More recently, this class of drugs has had labeling changes to reflect the increased risk of suicidal thinking and behavior in young adults.22,23

Side effects of SSRIs include the following:

  • Anxiety
  • Sedation
  • Insomnia
  • Decreased libido
  • Gastrointestinal disturbances (including nausea and indigestion)
  • Fatigue
  • Headache
  • Dry mouth
  • Dizziness
  • Tremor
  • Sweating
  • Weight gain

These side effects are generally manageable and may be reduced or eliminated by dose modification and use during the luteal phase only. There is no addictive potential and no tolerance with extended use of SSRIs. SSRIs are classified as Pregnancy Category C.

Orgasmic dysfunction (normal libido and arousal with delayed or absent orgasm) is the most problematic side effect of this class of drugs, reported in up to 80% of patients taking SSRIs continuously and for long duration.24

Sexual dysfunction can be managed by the following:3

  • Taking a watch and wait approach, as it may resolve on its own
  • Reducing the dose
  • Taking drug holidays
  • Substituting another SSRI agent
  • Augmenting treatment with various agents (such as bupropion)

Women who have been counseled to anticipate that it may be more difficult to achieve orgasm when using SSRIs and other serotonergic agents may be best equipped to manage this common side effect, often through communication with their partner. Many women experiencing relief of their PMS/PMDD symptoms may be so pleased with their improvement on SSRIs that they are willing to tolerate or adapt to the sexual dysfunction associated with use of this class of medications.


Unlike the use of SSRIs to treat depression, which may take 4–8 weeks to show efficacy, SSRIs used to treat PMS may reduce symptoms in a matter of days, and usually within 4 weeks after the start of treatment.23 For this reason, intermittent dosing with these medications can be used in some patients, thereby reducing prescription costs and side effects and increasing compliance. Other women prefer the simplicity of continuous daily dosing.

The doses of SSRIs needed to treat PMS are typically lower than those used to treat depression and anxiety.23 Table 4 shows the recommended doses of various SSRIs for the treatment of premenstrual disorders. Intermittent treatment is recommended, either during the luteal phase or on symptom days only.2


Table 4. Serotonergic Agents: Dosage and Administration for Treating Premenstrual Disorders

Fluoxetine (Prozac, Sarafem)** 20 mg/day
Sertraline (Zoloft)** 50–150 mg/day
Paroxetine (Paxil)** 10–30 mg/day
Citalopram (Celexa) 5–20 mg/day
Fluvoxamine (Luvox) 50–100 mg/day


Venlafaxine XR (Effexor25) 75–112.5 mg/day
Clomipramine 25–75 mg/day
* Consider starting women at lower doses to reduce side effects and improve adherence.
** Approved for the treatment of PMDD by the U.S. Food and Drug Administration.


Other Serotonergic Agents

Agents such as venlafaxine and clomipramine are also often used to treat PMDD.25 These agents inhibit the serotonin transporter as well as the uptake of norepinephrine and may be beneficial for some women who do not respond to or tolerate the “pure” SSRIs.2,15 Adding bupropion (a nonserotonergic agent) to a serotonergic antidepressant can boost antidepressant efficacy without increasing side effects such as orgasmic dysfunction. Nonserotonergic antidepressants, however, have not specifically been found to be effective in treating PMS.2

Oral Contraceptives

The use of oral contraceptives (OCs) reduces dysmenorrhea, intensity and duration of menstrual flow. Because premenstrual symptoms occur almost exclusively in ovulatory cycles, inhibiting ovulation could be expected to reduce or eliminate these symptoms.26 Hormonal contraceptives that suppress ovulation, including the pill, patch, vaginal ring, and depot-medroxyprogesterone acetate (DMPA) injections, offer effective relief from premenstrual symptoms for many women.

Because women using OCs for PMS often experience symptoms during the hormone-free interval, the selected treatment strategy should minimize or eliminate the hormone-free interval. Women may use monophasic OCs continuously, omitting the 7-day inert pills and starting a second pack immediately after the last active pill of their current pack. This regimen is safe and can be used indefinitely. Extended-regimen OCs, which are packaged with 84 days of active treatment with a 7-day pill-free interval (e.g., Seasonale®, Seasonique®), or continuous OC regimens (Lybrel®) may decrease hormone withdrawal symptoms, which include menstrually related headaches, cyclic mood swings, pelvic pain, and dysmenorrhea. Unscheduled bleeding is common during extended or continuous use of OCs. Provided that the patient has used OC tablets for a minimum of the last 21 days, taking a 3-day break from OC use and then resuming their use can reduce future episodes of unscheduled bleeding.27 Monthly OCs with a reduced hormone-free interval (Mircette®, LoEstrin 24®,YAZ®) may also have advantages over traditional 21/7 OC formulations in treating premenstrual symptoms.

Until recently, only limited data have assessed the efficacy of OCs in the treatment of PMS, and the few randomized trials have published conflicting results. However, two recently published multicenter randomized trials found that women’s PMDD symptoms were significantly reduced with a combination OC formulation (24 tablets containing drospirenone and ethinyl estradiol followed by 4 hormonally inert tablets).27,28 Drospirenone is a spironolactone antagonist that binds to the androgen receptor. This OC formulation had a greater impact on physical symptoms than placebo but also significantly improved mood symptoms. On the basis of these landmark trials, this 24/4 OC formulation with drospirenone (YAZ®), has received FDA approval for the treatment of PMDD, and also represents an OC formulation that clinicians and women may choose when PMS or other premenstrual symptoms are present.

If PMS or PMDD is diagnosed in a patient who is already using OCs, premenstrual symptoms may be reduced by switching to a formulation with a reduced hormone-free interval, to an extended continuous OC formulation, or to one that contains the progestin drospirenone.

Other Pharmacologic Agents

Other medications have been used to treat the symptoms of PMS/PMDD with various levels of success (Table 5).

Table 5. Other Pharmacologic Agents for the Treatment of PMS/PMDD15
Agent Type/Class Effective for Symptoms Notes
Alprazolam GABA agonist; benzodiazepine


Addictive and sedating. Should be reserved for intermittent use as a second-line agent.
Bromocriptine Dopamine agonist; lowers prolactin levels Breast tenderness Side effects may include dizziness and nausea.
Buspirone Partial serotonin agonist Anxiety No addictive potential.
Danazol Weak synthetic androgen; inhibits LH and FSH, suppressing ovarian steroid production Side effects limit use:

  • Amenorrhea
  • Weight gain
  • Acne
  • Fluid retention
  • Hirsutism
  • Hot flashes
  • Vaginal dryness
  • Emotional lability
GnRH agonists Reduce LH and FSH

Inhibits ovulation

Creates “pharmacologic menopause,” with associated menopause-like effects.

Should be reserved for women who do not respond to other treatments.

Add-back estrogen/progestin needed if continued >6 months.

NSAIDs Anti-inflammatory Dysmenorrhea Also reduce menstrual flow.
Spironolactone Potassium-sparing diuretic; anti-mineralocorticoid and anti-androgenic properties Bloating
Breast tenderness
Not highly effective.

Side effects:

  • Lethargy
  • Headache
  • Irregular menses

Monitor serum potassium levels.

FSH = follicle-stimulating hormone; GABA = gamma-aminobutyric acid; GnRH = gonadotropin-releasing hormone; LH = luteinizing hormone.

Patients should be advised not to take herbal preparations randomly or without consultation.

A few studies have examined the use of other forms of alternative therapies for the treatment of PMS/PMDD. Other alternative therapies women may want to explore include the following:15,30

  • Acupressure and acupuncture
  • Chiropractic and massage therapy
  • Homeopathic remedies
  • Hypnosis
  • Light therapy
  • Reflexology31
  • Vaginal biofeedback34
Table 6. Herbal Supplements Used for the Treatment of PMS/PMDD2,4,15,32
Product Notes
Evening primrose oil 500 mg per day to 1,000 mg t.i.d.
Most studied, but no safety data
Chaste tree extract (Vitex agnus-castus) 30–40 mg/day
Few adverse effects, but no safety data
Shown to be inferior to fluoxetine
St. John’s wort No controlled trials evaluating use for PMS
Possible drug interactions
Long-term effects unknown
Natural progesterone Shown to be ineffective in controlled trials
Gingko No controlled trials
Potential for drug interactions
Kava No controlled trials
Potential for hepatotoxicity
Dong quai No controlled trials
Unsafe in pregnancy
Contains coumarin derivative—should not be used by patients on anticoagulants
Black cohosh Stimulates estrogen receptors
Used to treat anxiety, breast pain
No controlled trials or safety data




  1. Dimmock PW, Wyatt KM, Jones PW, O’Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet. 2000;356:1131–6.
  2. Johnson SR. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners. Obstet Gynecol. 2004;104(4):845–59.
  3. Steiner M. Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for managment. J Psychiatry Neurosci. 2000;25(5):464-5.
  4. Bhatia SC, Bhatia SK. Diagnosis and treatment of premenstrual dysphoric disorder. Am Fam Physician. 2002;66(7):1239–48.
  5. Bowman MA. Premenstrual syndrome. In: Dambro MR, Griffith JA, eds. Griffith’s 5-Minute Clinical Consult. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:862–3.
  6. Freeman EW, Sondheimer SJ. Premenstrual dysphoric disorder: recognition and treatment. Primary Care Companion J Clin Psychiatry. 2003;5:30–9.
  7. Endicott J, Freeman EW, Kielich AM, Sondheimer SJ. PMS: new treatments that really work. Patient Care. 1996;30:88–123.
  8. Johnson WG, Carr-Nangle RE, Bergeron KC. Macronutrient intake, eating habits and exercise as moderators of menstrual distress in healthy women. Psychosom Med. 1995;57:324–30.
  9. Rapkin AJ. New treatment approaches for premenstrual disorders. Am J Manag Care. 2005;11(16 Suppl):S480–91.
  10. Bertone-Johnson ER, Hankinson SE, Bendich A, Johnson SR, Willett WC, Manson JE. Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch Intern Med. 2005;165(11):1246–52.
  11. Hardy ML. Herbs of special interest to women. J Am Pharm Assoc. 2000;40:234–42.
  12. Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology. 2003;28(Suppl 3):39–53.
  13. Thys-Jacobs S, Ceccarelli S, Bierman A, Weisman H, Cohen MA, Alvir J. Calcium supplementation in premenstrual syndrome: a randomized crossover trial. J Gen Intern Med. 1989;4(3):183–9.
  14. Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol. 1998;179(2):444–52.
  15. Kaur G, Gonsalves L, Thaker HL. Premenstrual dysphoric disorder: a review for the treating practitioner. Cleve Clin Med. 2004;71(4):303–21 passim.
  16. Maxson WS, Rosenwaks Z. In: Copeland LJ, Jarrell JF, eds. Textbook of Gynecology, 2nd ed. Philadelphia: W. B. Saunders, 2000:513–4.
  17. Ward MW, Holimon TD. Calcium treatment for premenstrual syndrome. Ann Pharmacother. 1999;33:1356–8.
  18. Parry BL, Rausch JL. Premenstrual dysphoric disorder. In: Kaplan HI, Sadock BJ, Cancro R, eds. Comprehensive Textbook of Psychiatry, 6th ed. Baltimore, MD: Williams & Wilkins, 1995:1707–13.
  19. Christensen AP, Oei TP. The efficacy of cognitive-behavioral therapy in treating premenstrual dysphoric changes. J Affect Disord. 1995;33:57–63.
  20. Krasnik C, Montori VM, Guyatt GH, Heels-Ansdell D, Busse JW, Medically Unexplained Syndromes Study Group. The effect of bright light therapy on depression associated with premenstrual dysphoric disorder. Am J Obstet Gynecol. 2005;193(3 Pt 1):658–61.
  21. Lam RW, Carter D, Misri S, Kuan AJ, Yatham LN, Zis AP. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res. 1999;86(3):185–92.
  22. American College of Obstetricians and Gynecologists. Premenstrual Syndrome. ACOG Practice Bulletin No. 15. Washington, DC: American College of Obstetricians and Gynecologists, 2000.
  23. Wyatt KM, Dimmock PW, O’Brien PM. Selective serotonin reuptake inhibitors for premenstrual syndrome (Review). Cochrane Library 2007(4):1–26.
  24. Balton R. SSRI-associated sexual dysfunction. Am J Psychiatry. 2006;163(9):1504–9.
  25. Cohen LS, Soares CN, Lyster A, et al. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol. 2004;24:540–3.
  26. Sulak PJ. Ovulation suppression of premenstrual symptoms using oral contraceptives. Am J Manag Care. 2005;11(16 Suppl):S492–7.
  27. Pearlstein TB, Bachman GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72:414–21.
  28. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492–501.
  29. 29. Sulak PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol. 2006;195(4):935–41.
  30. Domoney CL, Vashisht A, Studd JW. Premenstrual syndrome and the use of alternative therapies. Ann N Y Acad Sci. 2003;997:330–40.
  31. Campagne DM, Campagne G. The premenstrual syndrome revisited. Eur J Obstet Gynecol Reprod Biol. 2007;130(1):4–17.
  32. Ford O, Lethaby A, Mol B, Roberts H. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev. 2006;Oct 18(4):CD003415.
  33. Oleson T, Flocco W. Randomized controlled study of premenstrual symptoms treated with ear, hand, and foot reflexology. Obstet Gynecol. 1993;82:906–11.
  34. Van Zak DB. Biofeedback treatments for premenstrual and premenstrual affective syndromes. Int J Psychosom. 1994;41:53–60.
Drug Integrity Associate Audrey Amos is a pharmacist with experience in health communication and has a passion for making health information accessible. She received her Doctor of Pharmacy degree from Butler University. As a Drug Integrity Associate, she audits drug content, addresses drug-related queries

Leave a Comment